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Abstract
Background  and  objectives:  Achieving  good  clinical  practice  in  the  use  of  opioids  as  part  of  a
comprehensive  pain  management  regimen  can  face  signiﬁcant  challenges.  Despite  guidelines
from governmental  and  pain  society/organization  sources,  there  are  still  signiﬁcant  hurdles.
A review  of  some  basic  tenets  of  opioid  analgesia  based  on  current  published  knowledge  and
experiences  about  this  important  healthcare  imperative  is  warranted.
Content:  Consistent  with  guidelines,  the  literature  supports  using  the  lowest  total  opioid  dose
that provides  adequate  pain  control  with  the  fewest  adverse  effects.  Titration  (or  trial)  during
opioid initiation  is  a  way  of  starting  low  and  going  slow  (and  assessing  the  appropriateness  of  a
speciﬁc opioid  and  formulation).  Recognizing  that  multiple  factors  contribute  to  an  individual’s
personal  experience  of  pain,  the  physical,  psychological,  social,  cultural,  spiritual,  pharmacoge-
nomic, and  behavioral  factors  of  the  individual  patient  should  be  taken  into  account  (tweaking,
or tailoring).  Finally,  for  those  patients  for  whom  transition  (tapering)  from  opioid  is  desired,
doing so  too  rapidly  can  have  negative  consequences  and  minimization  of  problems  during  this
step can  be  achieved  by  proper  tapering.at  a  simultaneously  aggressive,  yet  conservative,  approach  is  advo-
which  opioid  therapy  is  divided  into  three  key  steps  (the  3  T’s):
g  (or  tailoring),  and  transition  (or  tapering).  Establishment  of  the
ication  of  other  appropriate  good  medical  practice  and  clinicalConclusion:  We  conclude  th
cated in  the  literature  in  
titration (or  trial),  tweakin
3 T’s  along  with  the  appl∗ Corresponding author.
E-mail: robert.raffa@temple.edu (R.B. Raffa).
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104-0014/© 2014 Sociedade Brasileira de Anestesiologia. Published by Elsevier Editora Ltda. All rights reserved.
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experience/judgment,  including  non-pharmacologic  approaches,  can  assist  healthcare
providers  in  the  effort  to  achieve  optimal  management  of  pain.
© 2014  Sociedade  Brasileira  de  Anestesiologia.  Published  by  Elsevier  Editora  Ltda.  All  rights
reserved.
PALAVRAS-CHAVE
Tratamento  da  dor;
Opioide;
Titulac¸ão;
Ajuste;
Reduc¸ão  gradual
Orientac¸ão  para  boa  prática  clínica  para  opioides  no  tratamento  da  dor:  os  três
‘‘Ts’’  --  titulac¸ão  (teste),  ajustes  (individualizac¸ão),  transic¸ão (reduc¸ão  gradual)
Resumo
Justiﬁcativa  e  objetivos:  A  realizac¸ão  de  uma  boa  prática  clínica  com  o  uso  de  opioides  como
parte de  um  regime  abrangente  de  tratamento  da  dor  pode  enfrentar  desaﬁos  signiﬁcativos.
Apesar das  diretrizes  provenientes  de  sociedades/organizac¸ões  não  governamentais  para  o
manejo da  dor,  ainda  existem  obstáculos  signiﬁcativos.  A  revisão  de  alguns  princípios  bási-
cos da  analgesia  com  opioide  com  base  na  experiência  e  conhecimento  das  publicac¸ões  atuais
sobre esse  cuidado  importante  da  saúde  é  justiﬁcável.
Conteúdo:  De  acordo  com  as  diretrizes,  a  literatura  apoia  o  uso  da  dose  total  mais  baixa  de  opi-
oides que  fornec¸a  o  controle  adequado  da  dor  com  menos  efeitos  adversos.  A  titulac¸ão  (teste)
ao iniciar  a  administrac¸ão  de  um  opioide  é  uma  maneira  de  comec¸ar  com  uma  concentrac¸ão
baixa e  ir  devagar  (avaliando  a  adequac¸ão  da  fórmula  especíﬁca  de  um  opioide).  O  ajuste
(individualizac¸ão) é  reconhecer  que  vários  fatores  contribuem  para  a  experiência  pessoal  da
dor de  um  indivíduo,  tais  como  fatores  físicos,  psicológicos,  sociais,  culturais,  espirituais,  far-
macogenômicos  e  comportamentais.  Finalmente,  para  aqueles  pacientes  nos  quais  a  transic¸ão
(reduc¸ão gradual)  do  opioide  é  desejada,  fazer  essa  transic¸ão  muito  rapidamente  podem  ter
consequências  negativas,  e  é  possível  minimizar  os  problemas  durante  essa  etapa  através  de
uma reduc¸ão  gradual.
Conclusão:  Concluímos  que  uma  abordagem  simultânea,  agressiva,  porém  conservadora  é
defendida  na  literatura  em  que  a  terapia  com  opioides  é  dividida  em  três  etapas  principais  (os
3 ‘‘Ts’’  --  em  inglês:  titration,  tailoring,  tapering):  titulac¸ão  (teste),  ajuste  (individualizac¸ão)
e transic¸ão  (reduc¸ão  gradual).  Estabelecer  os  três  Ts,  juntamente  com  a  aplicac¸ão  de  outra  boa
prática médica  e  experiência/julgamento  clínico,  incluindo  abordagens  não  farmacológicas,
podem  ajudar  os  proﬁssionais  de  saúde  no  esforc¸o  para  alcanc¸ar  o  tratamento  ideal  da  dor.
© 2014  Sociedade  Brasileira  de  Anestesiologia.  Publicado  por  Elsevier  Editora  Ltda.  Todos  os
direitos reservados.
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Current  estimates  indicate  that  as  many  as  100  million  Amer-
icans  are  suffering  from  a  chronic  pain  condition1 and  a
prevalence  of  10--50%  throughout  European  countries.2--4
Inadequate  pain  treatment  can  have  severe  consequences  at
both  the  individual  and  societal  levels.  For  individuals,  sim-
ple  daily  activities  can  be  difﬁcult  and  disruptions  in  one’s
routine  can  further  lead  to  mood  disorders  such  as  depres-
sion,  anxiety,  and  stress.5 Taken  together,  these  problems
can  decrease  a  patient’s  quality  of  life.  For  society,  pain
patients  place  a  burden  on  economic  productivity  and  the
healthcare  system.6
In  addition  to  non-pharmacologic  options,  there  are  sev-
eral  pharmacologic  options  for  the  treatment  of  pain,  as
promulgated  by  the  WHO  (World  Health  Organization)  pain
7‘ladder’  and  modiﬁcations. They  include  NSAIDs  (nons-
teroidal  anti-inﬂammatory  drugs),  acetaminophen,  weak
and  strong  opioids,  muscle  relaxants,  anticonvulsants,  and
antidepressants.  Most  of  these  are  adequate  to  treat  mild  to
e
r
h
qoderate  pain  in  the  short  term.  For  moderate-to-moderate
evere  pain,  strong  opioids  are  generally  considered  the  ﬁrst
hoice.  Opioids  have  become  increasingly  popular  in  treat-
ng  moderate  to  moderately  severe;  ‘‘around  the  clock’’
ain  conditions.  Their  efﬁcacy  for  short-term  pain  relief
as  been  documented  in  many  randomized  clinical  trials;
heir  long-term  beneﬁt/risk  ratio  for  non-cancer  pain  is  still
nder  debate.8--11 The  United  States  FDA  promotes  a  Risk
valuation  and  Mitigation  Strategy  (REMS).
Placing  a  patient  on  opioid  therapy  requires  more  than
ust  telling  them  to  take  it  as  indicated  within  the  prescrib-
ng  leaﬂet.  Pain  sensation  and  perception  are  different  for
ach  individual,  so  not  every  patient  will  respond  equally
o  the  same  drug.  Factors  such  as  age,  sex,  genetics,
nd  organ  function  all  play  a  role  in  analgesic  outcome.
hus,  administration  of  an  opioid  without  thorough  knowl-
dge  of  both  the  individual  and  the  opioid  can  potentially
esult  in  unsafe  and  inappropriate  use.  Unfortunately,  many
ealthcare  providers  have  not  had  the  opportunity  to  be  ade-
uately  trained  to  treat  pain  and  understand  the  complexity
3o
a
t
(
i
t
t
f
a
s
a
i
t
k
o
i
T
T
t
s
g
o
i
d
ﬁ
s
T
I
o
o
t
s
o
t
c
s
c
a
r
d
n
b
t
o
s
i
a
T
T
e
r
p
t
t
C
t
p
a
t
o
a
o
t
e
t
e
a
b
O
I
w
a
p
a
p
b
p
o
p
m
s
S
T
o
m
T
W
t
o
p
t
f
m
o
a
d
r
e
i
(
T
T12  
f  pain  and  use  of  analgesics,  especially  combinations  of
nalgesics,  to  treat  various  types  of  pain.
Inadequate  opioid  therapy  can  generally  be  traced  back
o  errors  during  a  few  key  stages  of  opioid  treatment
titration/trial/initiation,  tailoring/maintenance,  taper-
ng/rotation).  Speciﬁc  step-by-step  protocols  for  each  of
hese  stages  require  experience  and  education  since  pain
reatment  is  highly  individualized  and  dynamic.  Guidelines
rom  various  governmental  and  pain  societies/organizations
re  available  to  follow,  but  currently  there  is  no  univer-
al  opioid  guideline.10--18 In  order  to  facilitate  the  design
nd  implementation  of  rational  and  appropriate  opioid  reg-
mens,  it  is  helpful  to  differentiate  the  basic  steps  of  opioid
herapy.  In  this  review  we  seek  to  present  current  published
nowledge  and  experiences  regarding  three  important  steps
f  opioid  treatment:  titration  (or  trial),  tailoring,  and  taper-
ng  (The  3T’s).
itration (trial/initiation)
he  initiation  phase  of  opioid  therapy  is  a  critical  step
oward  achieving  the  greatest  beneﬁt  while  obtaining  the
upport,  trust,  and  compliance  of  the  patient.  The  ultimate
oal  is  to  be  able  to  provide  the  fastest  pain  relief  with-
ut  causing  an  emergence  of  adverse  effects.  However,  the
nitiation  of  opioids  is  not  the  same  for  every  patient  and
ifferent  regimens  may  need  to  be  implemented  (trial  of
rst  opioid  selection  followed,  if  necessary,  by  alternative
election),  based  on  the  type  of  pain  and  patient.19
ype  of  pain
t  is  best  if  the  healthcare  provider  can  determine  the  type
f  pain  the  patient  is  experiencing  (e.g.,  low-back  pain,
steoarthritis,  ﬁbromylagia)  and  determine  whether  opioid
herapy  is  appropriate.  For  example,  certain  pain  conditions
uch  as  ﬁbromyalgia  do  not  always  adequately  respond  to
pioids20 and  thus  might  currently  not  be  the  ﬁrst  choice  for
his  pain  condition.  Long-term  use  of  opioids  for  certain  pain
onditions,  e.g.,  low-back  pain  and  OA  (osteoarthritis)  are
till  under  debate.  The  effectiveness  of  opioids  in  these  non-
ancer  conditions,  as  well  as  the  potential  for  misuse,  abuse,
nd  side  effects  remain  major  issues.21 However,  short-term
elief  has  been  documented  for  many  pain  types  including
iabetic  neuropathy,  peripheral  neuropathy,  postherpetic
euralgia,  phantom  limb  pain,  spinal  cord  injury  with  pain
elow  the  level  of  injury,  lumbar  radiculopathy,  OA,  rheuma-
oid  arthritis,  low-back  pain,  and  neck  pain.14 In  the  course
f  cancer,  pain  can  start  out  as  mostly  nociceptive,  but  tran-
ition  (due  to  peripheral  and  central  sensitization)  occurs  to
nclude  hyperalgesia  and  a  neuropathic  component  (e.g.,
llodynia).
ype  of  patient  and  opioid  choice
he  choice  of  an  opioid  should  be  carefully  considered.  For
xample,  opioid-naïve  patients  run  a  higher  risk  of  expe-
iencing  adverse  effects  and  overdose.  Elderly  patients  or
atients  with  a  number  of  co-morbidities  may  beneﬁt  from
he  short  half  life  of  immediate  release  opioids  because  of
he  reduced  probability  of  overdose.22 Guidelines  by  the
d
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anadian  government  have  described  the  use  of  codeine  or
ramadol  as  ﬁrst-line  opioids  for  mild  to  moderate  chronic
ain  due  to  their  reduced  potential  for  misuse,  overdose
nd  addiction.14 If  pain  is  not  effectively  controlled  with
hese  opioids,  or  if  adverse  effects  are  experienced,  the  use
f  opioids  such  as  morphine,  oxycodone,  or  hydromorphone
re  described.  Other  ‘atypical’  opioids,  such  as  tapentadol
r  buprenorphine,  could  be  considered.23,24 Guidelines  by
he  Department  of  Veteran  Affairs  and  the  British  Pain  Soci-
ty  suggest  that  no  single  opioid  is  superior  over  others,
he  choice  should  be  made  based  on  local  experience  and
xpertise  and  that  selecting  the  correct  opioid  on  the  ﬁrst
ttempt  is  difﬁcult,  so  that  several  rounds  of  rotation  may
e  necessary.12,15
pioid  formulation
t  is  critical  that  the  temporal  setting  of  pain  be  matched
ith  the  appropriate  release-timing  of  the  opioid:  immedi-
te  release  for  initial  titration;  rapid  onset  breakthrough
ain;  and  extended-release  or  transdermal  patches  for
round-the-clock  analgesia.14 In  general,  patients  should  be
laced  on  sustained/extended  release  formulations  if  they
eneﬁt  from  a consistent  pharmacokinetic  proﬁle.  However,
atients  will  respond  differently  to  the  type  and  formulation
f  an  opioid  and  thus  it  is  up  to  the  healthcare  provider  and
atient  to  understand  that  several  rounds  of  opioid  rotation
ight  be  needed  in  order  to  ﬁnd  the  most  efﬁcacious  and
afe  option.25
tarting-dose
here  is  no  universal  agreement  on  the  starting-doses
f  individual  opioids.  The  various  initiation  doses  recom-
ended  in  several  guidelines  are  presented  in  Table  1.14,15
itration  procedure  --  general  rules  and  guidelines
ith  any  type  of  opioid  therapy,  the  end  goal  is  to  use
he  lowest  opioid  dose  that  provides  an  adequate  level
f  pain  control  and  a  tolerable  side  effect  proﬁle.  Some
roviders  take  the  approach  ‘start  low  and  start  slow’  and
his  approach  seems  reasonable.  One  of  the  major  reasons
or  slowly  and  incrementally  increasing  an  opioid  dose  is  to
inimize  adverse  effects.  Patients,  especially  those  who  are
pioid-naive,  require  time  to  adjust  to  the  opioid  effects.  In
ddition,  it  will  be  easier  for  providers  to  ﬁnd  the  optimal
ose  that  provides  the  right  balance  between  beneﬁts  and
isk.  Other  reasons  for  slow  titration  include:  patient  may
xperience  changes  that  alter  pain  perception  after  opioid
nitiation;  and  the  underlying  pain  condition  may  worsen
e.g.,  cancer  progression).
itration:  how  much  and  when  to  increase
here  are  no  set  guidelines  on  when  to  increase  opioid
osage,  because  it  is  very  difﬁcult  to  establish  a  general
uideline  when  pain  treatment  needs  to  be  individualized.
uidelines  for  appropriate  titration  have  not  been  tested
ormally  in  clinical  trials.  Some  guidelines  are  available.14,15
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Table  1  Initial  starting  dose  for  various  opioids.
Canadian
guidelinesa
Department  of
veteran  affairsa
Agency  medical
directors  group
(opioid  naïve)
American  society
of  interventional
pain  physicians
(opioid  naïve)
American  society
of  interventional
pain  physicians
(opioid
experienced)
Codeine  15--30  mg  every  6  h  30  mg  q  4--6  h  15  mg  bid  or  tid
CR codeine  50  mg  every  12  h
CR tramadol  100--150  mg  every
24  h
Not  recommended
IR morphine 5--10  mg  4--6  h
(max  40)
10--30  mg  q  4--6  h 10  mg  q  4  h Not  recommended 10  mg,  2--3×
CR morphine 10--20  mg  (max  40) 15  mg  q  8--12  or
30 mg  q  24  h
15  mg  q  12  h Not  recommended 15--30  mg,  2×
daily
IR oxycodone  5  mg  4--6  h  (max
30)
5  mg  q  6  h  5  mg  q  4--6  h  5--10  mg,  2--3×
daily
5--10  mg,  3--4×
daily
CR oxycodone  10  mg  (max
30  mg/d)
10  mg  q  12  h  10  mg  q  12  h  Not  recommended  10  mg  for  12  h
IR hydromorphone  1--2  mg  4--6  h  (max
8 mg/d)
2  mg  q  4--6  h  2  mg  q  4--6  h  2  mg  bid  or  tid  2--4  mg,  2--3×
daily
CR hydromorphone  3  mg  (max  9  mg/d)  Not  recommended  5--10  mg,  2×  daily
Hydrocodone 5--10  mg  q  4--6  h  5--10  mg  q  4--6  h  5--10  mg,  2--3×
daily
5--10  mg,
3--4×daily
IR oxymorphone  10--20  mg  q  4--6  h  5--10  mg  q  4--6  h  5  mg  bid  or  tid  5--10  mg,  2--3×
daily
IR tapentadol 50  mg  q  4--6  h
Tramadol 25  mg  daily 50  mg  bid  or  tid  50  mg,  3--4×  daily
CR oxymorphone 5  mg  q  12  h  10  mg  q  12  h  Not  recommended  10  mg  q  12  h
Transdermal fentanyl 25  mcg/h  q  72  h Not  recommended  12.5--25  mcg  q  72  h
New opioid formulations, recently introduced on the US and/or EU market, are not yet included in current guidelines. However, according
to published RCTs, the recommended starting doses are 10/5 mg BID (q 12 h) for ER (extended-release) oxycodone/naloxone and 50 mg
ate r
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TBID (q 12 h) for ER tapentadol. CR, controlled release; IR, immedi
a No distinction between opioid naïve vs. opioid experienced.
Particular  care  in  dosing  must  be  given  in  the  elderly,  espe-
cially  frail  elderly,  low  tolerant  opioid  patients,  and  those
experiencing  side  effects.  Careful  monitoring  should  always
accompany  every  titrated  dose.  Providers  should  also  pay
particular  attention  to  the  development  of  adverse  effects.
Titration:  when  to  stop
Optimal  dose  is  generally  considered  achieved  when  a
patient  has  experienced  a  ≥30%  reduction  in  pain  relief
(e.g.,  2  points  on  an  11-point  numerical  rating  scale)  and
no  serious,  or  tolerable,  side  effects  or  complications  on
the  dose.16,26,27 However,  all  of  these  are  meant  to  pro-
vide  general  guidance  only  and  the  actual  regimen  should
be  customized  to  each  patient.
Key  points  to  consider  when  determining  if  titration
needs  to  continue:
•  Lack  of  efﬁcacy.
•  Side  effects  have  become  intolerable.If efﬁcacy  is  not  achieved,  the  patient  should  be  re-
evaluated  or  opioid  rotation  or  formulation  change  should
be  considered.
M
p
celease.
weaking (tailoring/maintenance)
ain  assessment
ain  assessment  is  not  only  determining  a  patient’s  pain
ntensity  score.  There  are  many  factors  that  can  contribute
o  an  individual’s  chronic  pain  experience,  including  phys-
cal,  psychological,  social,  cultural,  spiritual,  genetic,  and
ehavioral  factors.  All  of  these  factors  should  be  assessed
n  order  for  optimal  management  to  occur.  Many  tools  are
vailable  to  assess  these  factors  and  it  is  up  to  the  health-
are  providers  and  the  patient  to  determine  which  ones
hey  prefer  to  use  at  initiation  and  throughout  treatment.
n  addition,  it  is  important  for  the  provider  to  understand
he  assessment  tool  in  order  for  the  physician  to  accurately
auge  the  impact  of  each  individual  factor.  A  list  of  common
ssessments  and  tools  that  should  be  considered  is  included
n  Table  2.
ype  of  patientanaging  pain  can  be  particularly  challenging  in  older
atients  who  often  have  comorbidities  or  physiological
hanges  that  affect  pharmacokinetics  or  side-effect  proﬁles
314  F.  Coluzzi  et  al.
Table  2  Types  of  assessment  and  tools  for  determining  appropriateness  of  opioid  therapy.13--15,22,48--54
Pain  related  history  Social  history  Risk  assessment  for  substance  abuse
Prior  pain  treatment Employment  Urine  test
Pain related  fear  Cultural  background  Use  of  risk  stratiﬁcation  tools
Pain interference  with  activities  Family  support  Risk  of  suicide
Medical history Legal  history
Allergies
Review  of  diagnostic  studies
Psychiatric  history  Physical  examination  Tools
Depression  Mental  status Screener  and  Opioid  Assessment  for  Patients
with  Pain  (SOAPP)  version  1
Anxiety disorders  Age  Revised  SOAPP  (SOAPP-R)
Emotional  disorders  Race  Opioid  Risk  Tool  (ORT)
Personality  disorders Gender  Diagnosis,  Intractability,  Risk,  Efﬁcacy  (DIRE)
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f  drugs.  The  general  approach  includes:  the  use  of  the
east-invasive  route  of  medication,  the  choice  of  sustained-
elease  formulations,  the  introduction  of  one  agent  at
 time,  at  the  lowest  effective  dose,  according  to  the
ule  ‘start  low,  go  slow’,  and  a  strict  monitoring  of  efﬁ-
acy  and  safety.  According  to  the  2009  American  Geriatrics
ociety  (AGS)  guidelines  on  pharmacological  treatment  of
ersistent  pain  in  older  adults,  acetaminophen  remains  the
rst-line  recommendation  among  the  non-opioid  class.28
SAIDs  pose  a  risk  for  causing  adverse  events  within
lder  adult  populations.  Their  use  should  be  limited,
articularly  in  patients  with  reduced  creatinine  clear-
nce,  gastropathy,  cardiovascular  disease,  or  congestive
eart  failure.  If  needed,  a  topical  formulation  should  be
referred.  Among  oral  NSAIDs,  naproxen  may  have  a  compar-
tively  lower  risk  of  cardiovascular  events.29 In  the  elderly,
SAIDs  and  cyclooxygenase-2  (COX-2)-selective  inhibitors
hould  only  be  used  in  rare  instances.30 Both  require
o-administration  of  an  agent  for  gastrointestinal  protec-
ion,  such  as  a  proton  pump  inhibitor,  if  the  therapy  is
xtended.
Opioids  are  not  excluded  from  use  for  older  adults.  Opi-
id  use  in  patients  >65  years  has  been  shown  to  have  similar
fﬁcacy  to  that  in  younger  adults.  In  fact,  there  is  a  current
rend  of  under-utilization  of  opioids  in  this  patient  popu-
ation  due  to  the  high  incidence  of  injuries  (falls  and  hip
ractures),  particularly  with  codeine  combinations31 plus  an
ncreased  risk  of  cognitive  impairment.32 Opioids  have  been
ecently  recognized  as  a  risk  factor  for  the  development  of
steoporosis,  therefore  it  is  reasonable  to  suspect  that  the
ncreased  incidence  of  fractures  observed  in  opioid  users
ould  be  related  to  reduced  bone  mass  density  secondary
o  the  effects  of  opioids  on  the  endocrinological  system.33
hysiological  changes  such  as  lower  serum-binding,  lower
troke  volume,  and  decreased  renal  function  might  play  a
ole  in  the  altered  pharmacokinetics  and  pharmacodynamic
ffects  of  opioids  in  this  patient  population.  The  adverse
vent  proﬁle  varies  greatly  between  opioids.  For  most  opi-
ids  except  buprenorphine,  the  half-lives  of  active  drug  and
etabolites  are  increased  in  the  elderly.  Special  considera-
ion  might  be  given  regarding  effects  on  respiration.  In  this
i
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egard,  buprenorphine  might  be  a  top-line  choice  for  opioid
reatment  in  the  elderly.34
o-morbidities
atients  with  impaired  liver  and/or  renal  function  are  at
ncreased  risk  of  accumulation  of  parent  drug  or  metabo-
ites,  which  can  lead  to  toxicity.  However,  not  all  opioids
ehave  the  same  in  renally  impaired  individuals  and  thus
t  is  up  to  the  prescriber  to  have  adequate  knowledge
n  what  opioid  and  what  dose  to  use  in  the  varying
evels  of  renal  impairment.  Guidelines  developed  by  the
uropean  Palliative  Research  Collaborative  stratisﬁed  opi-
ids,  based  on  current  literature,  into  groups  of  toxicity.35
entanyl,  alfentanil,  methadone,  and  tapentadol  are  not
nown  to  have  any  clinically  signiﬁcant  active  metabo-
ites  that  would  cause  toxicity  in  renally  impaired  patients.
ramadol  and  hydromorphone  (some  risk)  are  followed
y  morphine,  diamorphine,  codeine,  dihydrocodeine,  and
xycodone  (greater  risk)  and  by  pethidine  and  dextro-
ropoxyphene  (high  risk).  Others,  including  buprenorphine,
ufentanil,  and  remifentanil  have  limited  evidence  or  physi-
ian  experience  allows  for  recommendation  for  chronic  use.
In  patients  with  severe  liver  disease,  reduced  metabolism
sually  results  in  accumulation  of  the  parent  drug.  The
ytochrome  P450  enzymatic  system  is  usually  affected  in
he  early  stages  of  liver  impairment.  Therefore,  opioids
hat  depend  on  oxidation  for  their  metabolism,  such  as
ethidine,  dextropropoxyphene,  tramadol,  and  alfentanil,
ay  have  increased  oral  bioavailability  due  to  a  reduced
rst-pass  metabolism,  and/or  reduced  clearance  (even  in
atients  with  moderate  hepatic  dysfunction).  The  oral
ioavailability  morphine  might  increase  as  much  as  200%
n  liver  disorders.  Fentanyl  appears  safe  and  dose  adjust-
ents  generally  are  not  necessary.  Conversely  to  other
pioids,  codeine  may  have  reduced  efﬁcacy,  since  the  liver
s  required  for  biotransformation  of  the  drug  into  the  active
etabolite,  morphine.  Codeine,  tramadol,  methadone,  and
xymorphone  should  be  avoided  if  possible  in  moderate  to
evere  liver  impairment.15 In  general,  opioids  should  be
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prescribed  at  lower  doses  in  patients  with  severe  liver  dis-
ease,  with  extended  dosing  intervals  when  multiple  daily
doses  are  needed.36
Dysphagia  (difﬁculty  swallowing)  is  common  among
elderly  people  and  among  cancer  patients.  Swallowing  prob-
lems  can  cause  several  clinical  problems  that  complicate
administration  of  oral  solid  medications.  Moreover,  some
drugs,  including  opioids,  can  worsen  swallowing  problems
by  inducing  xerostomia  (dry  mouth)  and  by  decreasing  lower
esophageal  sphincter  (LES)  pressure.  For  patients  who  have
difﬁculty  swallowing  and  require  opioid  analgesics,  trans-
dermal  formulations  might  be  considered.37
Genetics
An  increasing  literature  demonstrates  that  individual  vul-
nerabilities  to  speciﬁc  pain  types  and  mechanisms  --  and
variation  in  response  to  pain  medication  --  might  be  partially
explained  or  predicted  by  the  patient’s  genetics.38 There
are  many  pharmacogenetic  factors  that  can  contribute  to
the  efﬁcacy  and  adverse  effects  of  analgesics,  especially
the  opioids:  polymorphisms  in  genes  encoding  for  proteins
controlling  the  enzymatic  metabolism  of  drugs  (e.g.,  CYP2D6
and  codeine),  the  transport  of  drugs  out  of  their  target  organ
(e.g.,  P-glycoprotein  and  fentanyl)  and  the  target  receptor
(e.g.,  mu-opioid  receptor  and  morphine).39
More  than  half  of  all  current  prescription  drugs  are
metabolized  by  the  cytochrome  P450  (CYP)  enzymes
(speciﬁcally  CYP2D6  and  CYP3A4).  Therefore,  drugs  metab-
olized  by  this  pathway  (phase  I  metabolism),  which
includes  many  opioids,  such  as  oxycodone,  codeine,  dihy-
drocodeine,  hydrocodone,  and  tramadol,  are  associated
with  an  increased  possibility  for  drug--drug  interactions.
CYP450  inhibitors  can  lead  to  excessively  high  serum  concen-
trations  of  the  parent  drug.  This  may  increase  the  incidence
of  side  effects  if  the  parent  drug  is  active  (e.g.,  oxy-
codone),  or  it  may  decrease  efﬁcacy  if  it  is  a  prodrug  (e.g.,
codeine).  Conversely,  CYP450  inducers  can  lead  to  lower
than  expected  serum  concentrations  of  the  parent  drug.  This
can  lead  to  a  reduced  effect  if  the  parent  drug  is  active  or
an  enhanced  effect  if  it  is  a  prodrug.  Moreover,  mutations  in
the  CYP2D6  gene,  which  occur  in  approximately  1%  to  7%  of
the  Caucasian  population,  can  either  decrease  or  increase
enzyme  activity,  leading  to  alterations  in  opioid  analgesia.40
The  future  promise  of  pharmacogenetics  is  an  individually
tailored,  rational  drug  regimen  that  maximizes  efﬁcacy  and
minimizes  adverse  events.  Pharmacogenetic  testing  could
be  the  alternative  to  one-size-ﬁts-all  prescribing  of  pain
medication.  However,  pharmacogenetic  testing  is  not  widely
applied  in  current  clinical  practice  and  drugs  which  do  not
undergo  signiﬁcant  metabolism  by  CYP  enzymes,  such  as
tapentadol,  morphine,  and  oxymorphone,  hydromorphone,
can  be  an  alternative.41
Gender
Over  the  past  20  years,  an  increasing  number  of  studies  have
suggested  sex  differences  in  response  to  pain  and  analgesics.
In  general,  it  has  been  suggested  that  the  prevalence  of
most  common  forms  of  pain  is  higher  among  women  than
men,  and  that  women  report  greater  pain  after  invasive
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rocedures  than  do  men.  Compared  with  men,  it  has  been
uggested  that  women  display  enhanced  sensitivity  to  most
orm  of  experimentally  induced  pain.42 It  has  been  suggested
hat  women  have  greater  opioid  receptor  analgesia.  Simi-
arly,  some  evidence  suggests  that  serotonergic  agents  may
e  more  efﬁcacious  in  alleviating  chronic  pain  in  women,43
hich  seems  reasonable  given  that  hormonal  and  neurobi-
logical  factors  can  directly  affect  nociceptive  responses.
owever,  women  have  been  traditionally  under-represented
n  clinical  trials.  Currently,  the  evidence  on  sex  differences
n  pain  response  is  thought  not  to  be  strong  enough  to  allow
ranslation  of  the  experimental  work  to  clinical  decision-
aking.44
ransition (tapering)
urrent  literature  support  for,  or  advice  about,  how  to
iscontinue  an  opioid  is  generally  lacking.  As  with  the  titra-
ion  step,  performing  this  step  too  rapidly  can  have  severe
onsequences  such  as  experiencing  opioid  withdrawal  symp-
oms.  These  are  generally  not  life  threatening  and  may
nclude  agitation,  anxiety,  muscle  aches,  insomnia,  sweat-
ng,  abdominal  cramping,  diarrhea,  nausea  and  vomiting.
ndividualized  process
he  provider  should  recognize  the  various  reasons  for  discon-
inuing  opioid  therapy  and  then  construct  a  plan  of  action
hat  is  individualized  to  the  patient.  As  a  general  guide-
ine,  patient  removal  off  an  opioid  should  occur  under  the
ollowing  circumstances:
 Intolerable  adverse  effects.
 Non-adherence  by  the  patient.
 Misuse  by  the  patient.
 Lack  of  analgesic  effect.
 Patient  request.
apering:  general  guidelines  and  goals
here  are  not  much  data  on  this  topic  and  guidelines  vary
ubstantially.15,16 Some  experts  recommend  that  the  longer  a
atient  has  been  on  opioids,  the  slower  the  tapering.  Since
he  range  is  quite  large,  physician  experience,  as  well  as
ppropriate  monitoring,  should  always  be  the  guide.
It  has  been  recommended  that  a  specialist  be  involved  in
he  tapering  of  certain  patients,  such  as:15
 Those  that  are  at  high  risk  of  aberrant  behaviors  (e.g.,
parasuicidal  acts,  dealing/selling  medications,  or  those
with  severe  impulse  control  disorders).
 Those  with  complicated  withdrawal  symptoms.
 Those  being  tapered  due  to  concern  about  development
of  addiction.
pioid  formulation  considerationsuring  the  tapering  process,  patients  may  experience  signs
f  opiate  withdrawal.  These  may  include,  but  not  be  lim-
ted  to,  gastrointestinal  symptoms  such  as  nausea,  vomiting,
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216  
nd  diarrhea,  musculoskeletal  symptoms,  insomnia,  anxi-
ty,  and  irritability.  Occurrence  of  symptoms  will  be  driven
y  the  speciﬁc  opioid,  the  speed  of  taper  and  patient
o-morbidities.  Some  opioids  might  be  easier  to  taper  than
thers.45 Appropriate  tests  that  could  be  administered  dur-
ng  the  process  to  monitor  the  patient  include  the  clinical
piate  withdrawal  scale  (COWS)  and  the  subjective  opiate
ithdrawal  scale.46,47 These  scales  can  provide  the  physician
ith  the  knowledge  of  whether  the  planned  tapering  process
eeds  adjustment.  During  the  tapering  process,  adjuvant
gents  should  be  considered  for  management  of  symptoms  of
ithdrawal.  In  addition,  patients  should  receive  psychoso-
ial  support  if  needed  during  the  process.
onclusion
ain  is  a  highly  individualized  process  and  no  one  single
harmacologic  or  non-pharmacologic  approach  completely
emoves  pain  in  100%  of  patients  100%  of  the  time  without
ny  side  effects.  This  is  why  multiple  options  are  needed  and
hy  the  options  must  be  optimized  to  the  individual  patient.
his  is  particularly  important  when  considering  opioid  ther-
py,  since  proper  opioid,  regimen,  and  patient  selection  are
aramount.  The  three  T’s  of  titration  (trial),  tailoring,  and
apering  are  useful  concepts  and  guides  for  rational,  safe,
nd  appropriate  opioid  prescribing  which  should  result  in
mproved  outcomes  and  opioid  optimization.
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